This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Sarcoma	Glycogen dependent kinase 3 (GSK3)	Zebrafish and cell culture studies suggest GSK3 inhibition could help treat embryonal rhabdomyosarcoma (ERMS). In human ERMS cells, GSK3 inhibitors identified from a screen of about 40,000 compounds decreased growth compared with vehicle. In zebrafish with ERMS tumors, a GSK3 inhibitor suppressed tumor growth, depleted tumor-propagating cells and prevented tumor cell self-renewal, whereas vehicle did not. Next steps could include testing GSK3 inhibitors in mouse models of ERMS. SciBX 7(16); doi:10.1038/scibx.2014.458 Published online April 24, 2014	Patent and licensing status unavailable	Chen, E.Y. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 24, 2014; doi:10.1073/pnas.1317731111 Contact: David M. Langenau, Massachusetts General Hospital, Boston, Mass. e-mail: dlangenau@mgh.harvard.edu Contact: Xu Wu, Harvard Stem Cell Institute, Cambridge, Mass. e-mail: xwu@cbr2.mgh.harvard.edu